Marker Therapeutics (MRKR) News Today $1.05 -0.03 (-2.78%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$1.05 0.00 (0.00%) As of 07:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRKR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Marker Therapeutics Launches Phase 1 RAPID Trial for Multi-Antigen Recognizing T Cells as Off-the-Shelf Treatment for AML and MDSOctober 6, 2025 | quiverquant.comQMarker Therapeutics Announces First Patient Treated in Off-the-Shelf ProgramOctober 6, 2025 | globenewswire.comMarker Therapeutics, Inc. (NASDAQ:MRKR) Receives $13.17 Consensus Target Price from AnalystsOctober 6, 2025 | americanbankingnews.comMarker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | globenewswire.comMarker Therapeutics (MRKR) Falls 20.6% After Positive Clinical StudyAugust 27, 2025 | insidermonkey.comMarker Therapeutics stock soars on promising Phase 1 lymphoma study dataAugust 26, 2025 | investing.comMarker Therapeutics provides update on observations from Phase 1 APOLLO studyAugust 26, 2025 | msn.comMarker Therapeutics Stock Drops After Report About Lymphoma TreatmentAugust 26, 2025 | benzinga.comMarker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed LymphomaAugust 26, 2025 | globenewswire.comMarker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | globenewswire.comMarker Therapeutics Insider Trading Activity | NASDAQ:MRKR | BenzingaJuly 18, 2025 | benzinga.comHere's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn SituationJuly 11, 2025 | finance.yahoo.comMarker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with LymphomaJune 17, 2025 | globenewswire.comMarker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with LymphomaMay 20, 2025 | globenewswire.comMarker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell TherapiesMay 19, 2025 | globenewswire.comMarker Therapeutics (MRKR) Receives a Buy from Canaccord GenuityApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology ConferenceApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology ConferenceApril 1, 2025 | globenewswire.comMarker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last yearMarch 31, 2025 | markets.businessinsider.comMarker Therapeutics Reports Year-End 2024 Corporate and Financial ResultsMarch 31, 2025 | globenewswire.comMarker Therapeutics stockholder vote clears warrant issuanceMarch 28, 2025 | investing.comMarker Therapeutics initiated with a Buy at CanaccordMarch 5, 2025 | markets.businessinsider.comCanaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy RecommendationMarch 5, 2025 | msn.comMarker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 25, 2025 | globenewswire.comMRKR stock touches 52-week low at $1.61 amid market challengesFebruary 12, 2025 | msn.comBrookline Capital sets $4 target on Marker Therapeutics stockFebruary 11, 2025 | msn.comMarker Therapeutics initiated with a Buy at BrooklineFebruary 11, 2025 | markets.businessinsider.comMRKR stock touches 52-week low at $1.8 amid market challengesJanuary 31, 2025 | msn.comMarker Therapeutics Announces Board ResignationJanuary 31, 2025 | msn.comMRKR stock touches 52-week low at $2.4 amid challenging yearJanuary 21, 2025 | msn.comMarker Therapeutics files to sell 10.06M shares of common stock for holdersJanuary 10, 2025 | markets.businessinsider.comInsider Buying: Marker Therapeutics, Inc. (NASDAQ:MRKR) Director Acquires 11,085 Shares of StockDecember 27, 2024 | insidertrades.comEnterprise Associates 16 New Buys 554,250 Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) StockDecember 24, 2024 | insidertrades.comMarker Therapeutics sells 5.03M shares at $3.20 in private placementDecember 20, 2024 | markets.businessinsider.comMarker Therapeutics Announces $16.1 Million Private PlacementDecember 19, 2024 | globenewswire.comMarker Therapeutics Provides a Clinical Update on MT-601 in Patients with LymphomaDecember 19, 2024 | globenewswire.comMarker Therapeutics Awarded $9.5 Mln Grant From CPRIT For MT-601 In Metastatic Pancreatic CancerDecember 17, 2024 | markets.businessinsider.comMarker Therapeutics pops on receiving $9.5M grant to advance lead assetDecember 17, 2024 | msn.comMarker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors SymposiumDecember 10, 2024 | globenewswire.comBaylor College of Medicine-partnered Marker Therapeutics files for $11.4M offeringDecember 4, 2024 | bizjournals.comMarker Therapeutics to Present at the Citizens JMP Hematology and Oncology SummitNovember 26, 2024 | globenewswire.comMarker Therapeutics Advances in Clinical Trials and FinancesNovember 15, 2024 | markets.businessinsider.comMarker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 14, 2024 | globenewswire.comJason MarkerNovember 4, 2024 | sfgate.comMarker Therapeutics price target raised to $19 from $11 at LadenburgOctober 23, 2024 | finance.yahoo.comSportsZone Saturday: Dakota Marker Preview, USD offense rolls, remembering SID KortemeyerOctober 20, 2024 | msn.comLate touchdown lifts NDSU over SDSU in Dakota MarkerOctober 20, 2024 | msn.comKids Marker Market to hit USD 257.4 million by 2032, says Global Market Insights Inc.October 16, 2024 | finance.yahoo.comNewly discovered genetic marker could pave the way for future Alzheimer's disease therapeuticsOctober 9, 2024 | msn.comMarker Therapeutics (NASDAQ:MRKR) Stock, Short Interest ReportOctober 7, 2024 | benzinga.com Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRKR Media Mentions By Week MRKR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRKR News Sentiment▼0.780.77▲Average Medical News Sentiment MRKR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRKR Articles This Week▼51▲MRKR Articles Average Week Get the Latest News and Ratings for MRKR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Marker Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Actinium Pharmaceuticals News Estrella Immunopharma News Aadi Bioscience News RenovoRx News PDS Biotechnology News FibroGen News Oncobiologics News Tempest Therapeutics News Neuphoria Therapeutics News Medicus Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRKR) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredElon callingElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
